We scan new podcasts and send you the top 5 insights daily.
Although the DESTINY-Breast09 trial omitted a maintenance phase following trastuzumab deruxtecan and pertuzumab, Dr. Hamilton notes oncologists will likely transition patients off therapy upon reaching maximal response. Clinicians expect to integrate tucatinib maintenance without randomized data to support long-term quality of life.
The DESTINY-Breast09 trial compared continuous TDXD+pertuzumab against THP, which was largely treated as a short induction followed by maintenance. This design difference—continuous therapy versus induction/maintenance—may contribute to the superior outcomes seen with the TDXD arm, making it a slightly uneven comparison.
A patient on trastuzumab deruxtecan (TDXD) for seven years with no evidence of disease and no toxicity chose to continue the drug, declining to switch to a standard maintenance regimen. This illustrates a real-world challenge where patient preference and excellent outcomes can override the clinical logic of treatment de-escalation.
Data from DESTINY-Breast09 shows TDXD plus pertuzumab dramatically improved progression-free survival in first-line metastatic HER2+ breast cancer. This unprecedented efficacy raises new questions about optimal treatment duration and the potential for de-escalated maintenance therapy after induction.
While the PATINA regimen is effective after THP induction, no data supports switching to this maintenance after first-line TDXD-based therapy. Clinicians making this switch are operating in a "data-free zone" and extrapolating from different trial populations.
Beyond rigid trial protocols, a flexible approach to first-line T-DXd is practical and patient-centered. This includes discussing treatment breaks for holidays or switching to a less burdensome maintenance regimen (like subcutaneous HP) if a patient is tired of frequent clinic visits, prioritizing their quality of life.
DESTINY-Breast09 data shows that complete responses with TDXD+pertuzumab can take 8-10 months to develop. This suggests the regimen is not just a short induction strategy and may offer the greatest benefit for durable remission in lower-burden patients, countering the instinct to de-escalate.
In the DB09 trial, the median progression-free survival (40 months) was double the median duration of TDXD treatment (20 months). This discrepancy suggests many patients discontinued the cytotoxic component and effectively entered a maintenance phase, validating the induction-maintenance model even within a continuous therapy trial design.
To mitigate long-term toxicity from TDXD, oncologists are proposing an "induction/maintenance" approach. Patients receive TDXD for an initial period to achieve maximal response, then switch to a less toxic maintenance regimen for a "chemotherapy holiday," improving quality of life.
Based on recent trial data, the optimal maintenance strategy for HER2+ metastatic breast cancer differs by subtype. The speaker suggests palbociclib for hormone receptor-positive patients and tucatinib for hormone receptor-negative patients, reflecting a personalized, data-driven treatment approach.
The new standard for first-line HER2+ breast cancer, TDXD-pertuzumab, has superior efficacy. However, experts are questioning if treating until disease progression is optimal for all, suggesting a switch to maintenance therapy could better balance side effects and quality of life. The ideal duration remains an open question.